Cultivation, manufacturing and GMP

The legal pathway for medicinal cannabis in New Zealand is not a licence to grow or use cannabis. It is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975, and the products you can be prescribed are manufactured pharmaceuticals, not raw plant material sold over a counter. The single question that matters for anyone working in or entering this sector, whether you are a prescriber, a pharmacist, a patient, or an industry professional, is: what quality and regulatory system separates a legal medicinal cannabis product from an illegal one in New Zealand?

The answer is the Medicinal Cannabis Scheme, run by the New Zealand Ministry of Health through the Medicinal Cannabis Agency (MCA) within Medsafe. The scheme does not legalise cannabis generally. It creates a controlled pathway: a medical practitioner can prescribe an approved product, a pharmacist dispenses it, and every product must meet Good Manufacturing Practice (GMP) standards. The legal product is a manufactured pharmaceutical. Raw plant material, even if it is labelled “medicinal”, is only legal when it is a prescribed pharmaceutical product dispensed through a pharmacy. This page maps that quality system and gives you a practical checklist to verify any product, claim, or prescriber.

The legal framework: the Medicinal Cannabis Scheme

New Zealand’s medicinal cannabis regime is set out in the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. The Ministry of Health runs the Medicinal Cannabis Scheme through the Medicinal Cannabis Agency (MCA), which sits within Medsafe. The scheme does not legalise cannabis generally; it creates a controlled pathway for patients who have a prescription from a medical practitioner. Products must meet GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health before they can be prescribed and dispensed.

Key legal boundaries (effective since 1 April 2020, when the scheme’s product standards came into force):

• A prescription from a medical practitioner is required. The Misuse of Drugs Act 1975 and the Misuse of Drugs Regulations 1977 govern the pathway. A doctor may prescribe a “controlled drug” such as THC-containing cannabis under Section 22A of the Misuse of Drugs Amendment Act 2018.
• The legal product is a manufactured pharmaceutical. Raw plant material, when prescribed, is dispensed through a pharmacy as a manufactured product, not sold in a dispensary or café. Smoking raw flower is not covered by the scheme.
• Products must meet Good Manufacturing Practice (GMP) and be approved by the Ministry of Health (Medsafe) under the Medicinal Cannabis Scheme. The scheme began on 1 April 2020.
• A prescription from a medical practitioner is mandatory. No self-referral, no “cannabis clinic” bypass, no over-the-counter sale.
• The Misuse of Drugs Act 1975 governs the framework; medicinal cannabis is a controlled drug, not a general licence.

EFFECTIVE DATE: 2020-04-01

REGULATORY FRAMEWORK: - Medicinal Cannabis Scheme: Established by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, fully operational 1 April 2020. - Medsafe: The New Zealand Medicines and Medical Devices Safety Authority, which approves quality standards and product notifications. - Medicinal Cannabis Agency (MCA): Part of Medsafe, manages licensing, product approvals, and compliance. - Prescription: Issued by an authorised prescriber; a standard prescription is not valid for cannabis. - Misuse of Drugs Act 1975: Governs controlled drugs; medicinal cannabis products are Schedule 1 or 2 depending on THC content. - NZ Formulary: Contains official prescribing guidance, including cannabis product monographs.

Introduction

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act, not a general licence to use cannabis. The Medicinal Cannabis Scheme, run by the Ministry of Health, legalises access through a prescription from a medical practitioner, and products must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products; the legal product is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

What “medicinal cannabis” means under New Zealand law

Under the Misuse of Drugs Act 1975, cannabis remains a controlled drug. The Medicinal Cannabis Scheme, administered by the Ministry of Health and the Medicinal Cannabis Agency (MCA), creates a narrow, regulated exception: a medical practitioner can prescribe a cannabis product that has been manufactured to pharmaceutical standards and approved for supply. The scheme came into force on 1 April 2020. It does not legalise recreational use, and it does not allow a patient to grow, buy or smoke raw plant material outside a prescription pathway.

The key legal boundary is the product, not the plant. Under the scheme, a “medicinal cannabis product” must be a pharmaceutical-grade preparation that meets GMP standards and has been notified to the Ministry of Health. Raw dried flower can be prescribed and dispensed through a pharmacy, but it is still a manufactured, quality-assured product, not a loose herb. Smoking is not an approved administration route; the Misuse of Drugs Act and the scheme permit prescribed products, but the Ministry of Health’s guidance is clear that vaping or vaporising is the inhaled route, not smoking (New Zealand Ministry of Health, 2023).

The legal framework changed in 2020. The Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 came into force on 1 April 2020, creating the Medicinal Cannabis Scheme. Under this scheme, a medical practitioner can prescribe a CBD or THC product that meets GMP and Ministry of Health approval. The Ministry of Health has published the minimum quality standards for medicinal cannabis products, and the Medicinal Cannabis Agency (MCA) issues licences and product approvals. As of 2024, Medsafe maintains the public list of approved products, and the NZ Formulary lists cannabis monographs for prescribers.

The regulatory pathway does not allow a general licence to use cannabis. A prescription from a doctor is required, and the product must be a manufactured pharmaceutical. Smoking raw plant material is not an approved route; the only legal flower is dried cannabis that is prescribed and dispensed through a pharmacy, typically for vaporisation. The Medicinal Cannabis Scheme, established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, legalised access via prescription and set quality standards. Since 1 April 2020, the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 have been in force, creating the framework for GMP certification and product approval.

Cultivation is licensed and controlled; it is not something a patient can do at home. Under the scheme, the Ministry of Health licenses growers and manufacturers under the Misuse of Drugs Act. A licence is required for any activity involving controlled drugs, including cultivation, production, manufacture, and supply. As of 2024, the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 specify that only licensed persons may cultivate medicinal cannabis; there is no provision for home cultivation by patients, even with a prescription. The Medicinal Cannabis Agency (MCA) within Medsafe issues these licences and inspects facilities to ensure GMP compliance.

PRIMARY SOURCE (ATTRIBUTABLE): Misuse of Drugs (Medicinal Cannabis) Regulations 2019, New Zealand Legislation; Medsafe, Medicinal Cannabis Agency (MCA) guidance; New Zealand Ministry of Health medicinal cannabis pages; NZ Formulary; Healthify; product datasheets from Tilray, Medleaf, NUBU, Aurora, Cann Group, Spectrum Therapeutics, LGP Classic, Helius, MedReleaf, Bedrocan, Cannabisol, Eve.

CORE CONTENT OUTLINE: - Deciding whether GMP is mandatory: Legal pathway, the Misuse of Drugs Act and the Medicinal Cannabis Scheme - The three regulated categories (pharmaceutical grade, raw material, and “CBD only” products) - How a prescription actually works in NZ: who prescribes, what is dispensed, what is not allowed - What GMP means in practice: facility certification, quality control, batch testing, stability, and the role of Medsafe and the Medicinal Cannabis Agency - What a product label must tell you (and what it does not) - A practical decision rule for choosing a product category (flower vs oil vs oral capsule) - Red flags that indicate a product or vendor is not part of the regulated scheme - A short checklist for patients and clinicians before a prescription is written - Where to go next: NZ Formulary, Healthify, Medsafe, and the prescribing pathway